Format

Send to

Choose Destination
Adv Ther. 2018 Feb;35(2):243-253. doi: 10.1007/s12325-017-0652-2. Epub 2017 Dec 21.

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.

Author information

1
Department of Medicine, University of Padua, Padua, Italy.
2
Humanitas Research Hospital, Rozzano, MI, Italy.
3
IRCCS INRCA, Ancona, Italy.
4
ASST Bergamo Ovest, Treviglio, BG, Italy.
5
Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy.
6
Ospedale di Livorno, Livorno, Italy.
7
Department of Systems Medicine, University Tor Vergata, SG Calibita Fatebenefratelli, Rome, Italy.
8
IRCCS Centro Cardiologico Monzino, Milan, Italy.
9
Ospedale La Colletta, ASL3 Genovese, Arenzano, Italy.
10
Centro Regionale di Riferimento Diabetologia ed Impianto Microinfusori Sicilia, Partinico, Palermo, Italy.
11
Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
12
IRCCS Multimedica-Ospedale di Castellanza, Varese, Italy.
13
Presidio Ospedaliero di Cittadella, Cittadella, Padua, Italy.
14
Novo Nordisk Spa, Rome, Italy.
15
CORESEARCH-Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy. nicolucci@coresearch.it.

Abstract

INTRODUCTION:

The aim of the study was to evaluate whether the reduction in glycated hemoglobin (HbA1c) observed in clinical trials with liraglutide in type 2 diabetes (T2D) could be attained in routine clinical practice.

METHODS:

ReaL was a multicenter, non-interventional, observational, retrospective, longitudinal study on the effectiveness of liraglutide, a human glucagon-like peptide-1 analog, in individuals with T2D treated in daily practice in Italy. Between 26 March and 16 November 2015, data were taken from clinical records of patients aged ≥ 18 years with treatment follow-up data of up to 24 months and who received their first prescription of liraglutide in 2011.

RESULTS:

A total of 1723 patients were included in the analysis. At baseline, mean age was 58.9 years, duration of diabetes was 9.6 years, and HbA1c was 8.3%. At 12 months, 36.1% of patients were prescribed the maximum 1.8 mg dose; 43.5% [95% confidence interval (CI): 40.9; 46.2] of patients attained the primary outcome of a reduction in HbA1c of ≥ 1% point at 12 months. At 24 months, 40.9% (95% CI 38.1; 43.7) of patients had attained the HbA1c target of ≤ 7%. Additionally, body weight significantly decreased by 3.4 kg (95% CI - 3.6; - 3.1, p < 0.0001).

CONCLUSION:

In this observational study conducted in routine clinical practice for up to 2 years, treatment with liraglutide improved HbA1c and reduced body weight in a similar fashion to that observed under randomized clinical trial conditions. The data support the use of liraglutide as an effective treatment for T2D in clinical practice.

FUNDING:

Novo Nordisk S.p.A.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT02255266.

KEYWORDS:

Clinical practice; Diabetes; Effectiveness; Glycemic control; Italy; Liraglutide

PMID:
29270781
PMCID:
PMC5818560
DOI:
10.1007/s12325-017-0652-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center